Peroxiredoxins (Prx), a family of peroxidases that reduce intracellular peroxides with the thioredoxin system as the electron donor, are highly expressed in various cellular compartments. Among the antioxidant Prx enzymes, Prx2 is the most abundant in mammalian neurons, making it a prime candidate to defend against oxidative stress. Here we report that Prx2 is S-nitrosylated (forming SNOPrx2) by reaction with nitric oxide at two critical cysteine residues (C51 and C172), preventing its reaction with peroxides. We observed increased SNO-Prx2 in human Parkinson's disease (PD) brains, and S-nitrosylation of Prx2 inhibited both its enzymatic activity and protective function from oxidative stress. Dopaminergic neurons, which are lost in PD, become particularly vulnerable. Thus, our data provide a direct link between nitrosative/oxidative stress and neurodegenerative disorders such as PD.
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nitric oxide ͉ nitrosative stress ͉ thioridoxin ͉ sulfiredoxin ͉ peroxides P eroxiredoxins (Prx) are highly abundant and widely expressed antioxidant enzymes (1) (2) (3) . In addition to the direct reduction of H 2 O 2 mediated by Prx, the observations that Prx1 interacts with c-Myc (4) and c-Ab1 (5) and that Prx2 regulates PDGF receptor signaling (6) suggest that Prx are important factors linking reactive oxygen species metabolism to redox signaling events. Prx2 levels are significantly increased in neurodegenerative disease (7, 8) . Because oxidative stress plays an important role in the pathogenesis of neurodegenerative disorders (9, 10) , Prx2 up-regulation might counteract oxidative insults during neurodegeneration. Along these lines, Prx have been shown to protect hippocampal neurons from excitotoxic/oxidative injury in vivo (11) . Besides regulation of H 2 O 2 signaling by Prx, recent reports also show that oxidative stress shifts Prx from low-molecular-weight species to high-molecular-weight complexes, triggering a peroxidase-to-chaperone functional switch (12) and regulating cell-cycle arrest in C10 mouse lung epithelial cells (13) .
Nitric oxide (NO) represents a pleiotropic signaling molecule regulating diverse cellular processes that is produced endogenously from L-arginine by NO synthases. The classical NO signaling pathway is mediated by the generation of cGMP to regulate protein kinase G. However, in the past several years, protein S-nitrosylation, covalent attachment of a ϪNO group to a cysteine thiol (14) (15) (16) , has been recognized as a reversible posttranslational modification by which NO regulates the function of many target enzymes, transcription factors, and ion channels, such as Parkin (17, 18) , NMDA receptors (19, 20) , protein disulfide isomerase (21), NF-B (22), matrix metalloproteinases (23) , and other important proteins (24) (25) (26) (27) (28) (29) . Oxidative and nitrosative stress are thought to play important roles in neurodegeneration (9, (30) (31) (32) . However, the pathogenic mechanisms underlying this relationship have not been fully elucidated. Here we report that Prx2 activity is regulated by NO in vitro and in vivo by S-nitrosylation of redox-active cysteine residues in Prx2, forming SNO-Prx2. S-nitrosylation of Prx2 inhibits its protective function against oxidative stress-induced neuronal cell death. This finding provides a mechanistic link between nitrosative/oxidative stress and neurodegenerative disorders.
Results

S-Nitrosylation of Prx2 in Vitro and in Vivo.
Initially, we obtained in vitro evidence that Prx2 was S-nitrosylated by the naturally occurring NO-related species, S-nitrosocysteine (SNOC). After exposure to SNOC, Prx2 in lysates obtained from human SH-SY5Y cells was S-nitrosylated as detected by the biotin-switch method (15, 17, 21) . In this assay, SNO-Prx2 was identified on Western blots by replacing the NO group with a more stable biotin group after chemical reduction with ascorbate as described previously (17, 21) . SNOC enhanced SNO-Prx2 levels in cell lysates in a dose-dependent manner (Fig. 1A) , whereas under the same conditions exposure to hydrogen peroxide did not (data not shown). When we exposed intact SH-SY5Y cells (Fig. 1B) to SNOC, we also detected SNOPrx2. Additionally, we found that SNO-Prx2 was stable even 24 h after SNOC exposure (Fig. 1C) . Next, we determined whether endogenous NO could nitrosylate Prx2. For this purpose, HEK-293 cells stably expressing neuronal NO synthase (nNOS) were exposed to calcium ionophore to activate nNOS. In this experiment, we found that endogenous Prx2 could be S-nitrosylated by endogenous NO, and this reaction was inhibited by the NOS inhibitor, N-nitro-L-arginine (NNA) (Fig. 1D) .
Next, we determined whether Prx2 could be S-nitrosylated by NO in primary neuronal cultures. Exposure of primary neurons to SNOC stimulated SNO-Prx2 formation (Fig. 1E) . Excitotoxic damage is thought to be critical in neurodegenerative disorders such as Parkinson's disease (PD) through production of free radicals, including NO, in part by excessive stimulation of NMDA-type glutamate receptors. Therefore, we exposed primary wild-type (WT) or nNOS knockout (KO) neurons to NMDA and found that this procedure induced SNO-Prx2 in an NOS-sensitive fashion (Fig.  1F ). These data demonstrate that endogenous Prx2 in neurons is S-nitrosylated by both exogenous and endogenous NO. Moreover, inhibition of SNO-Prx2 formation by NNA or in nNOS KO neurons suggests that a pathophysiologically relevant amount of NO was produced under these conditions. Prx1-4 manifest a conserved redox-active site that reduces H 2 O 2 at cysteine residues 51 and 172. To determine the targets of S-nitrosylation on Prx2, we mutated these cysteines and assayed for SNO-Prx2 formation by using the biotin-switch method. HEK-293T cells were transfected with expression vectors encoding WT myc-Prx2 or mutant forms of the protein. Twentyfour hours later, cell lysates were exposed to SNOC or control conditions and monitored for SNO-Prx2. As opposed to single mutations, the C51A/C172A double mutant displayed almost no signal, suggesting that both residues were S-nitrosylated ( Fig.  2A) . To verify this result, we performed a chemical assay for S-nitrosylation on immunoprecipitates from HEK-293T cells transfected with WT or C51A/C172A double-mutant Prx2. For this purpose, we used the 2,3-diaminonaphthalene (DAN) assay, which monitors the release of the NO group from thiol by conversion of DAN to the f luorescent compound 2,3-naphthyltriazole (17, 21, 33) . The fluorescence intensity of double mutant Prx2(C51A/C172A) decreased by Ϸ80%, compared with WT, indicating that Cys-51 and Cys-172 are the predominant targets for S-nitrosylation on Prx2 (Fig. 2B) . As a control, Western blotting indicated that equivalent amounts of protein had been immunoprecipitated by the anti-myc antibody (Fig. 2B Inset) . (Fig. 3A) . Consistent with prior reports that the double mutant Prx2(C51A/C172A) lacks catalytic activity (40), we found that this mutant had no effect on hydrogen peroxide levels in the presence or absence of SNOC. Additionally, in intact SH-SY5Y cells, we found that pretreatment with SNOC decreased the reduction of H 2 O 2 by Prx2 (Fig. 3B) . Moreover, exposure of SH-SY5Y cells to SNOC resulted in the formation of SNO-Prx2 and inhibited 100 M H 2 O 2 -induced overoxidation of Prx2, as evidenced by less generation of PrxSO 2/3 H (Fig. 3C Right) . This finding suggests that SNO-Prx2 does not reduce H 2 O 2 as efficiently as WT Prx2. Increasing the concentration of H 2 O 2 could overcome this effect probably by promoting further oxidation (23) .
S-Nitrosylation of Prx2 Impairs Its Antioxidant
To demonstrate the relevance of these findings to neurodegenerative disease models, we transiently transfected WT myc-Prx2 (P) or C51A/C172A double-mutant myc-Prx2 (M) into SH-SY5Y cells and evaluated their protective effects after H 2 O 2 challenge in the presence or absence of NO. For this purpose, we used the dopaminergic SH-SY5Y cells because, unlike nigrostriatal or cerebrocortical neurons, they are resistant to direct NO-induced damage under conditions of SNO-Prx2 formation, allowing us to tease apart the effect of NO and Prx2 S-nitrosylation on cell death. WT Prx2 protected against H 2 O 2 -induced cell death, whereas the doublemutant Prx2 did not (Fig. 3D ). However, after SNOC pretreatment, the protective effect of WT Prx2 against H 2 O 2 significantly decreased. One concern with this kind of transient transfection experiment is the potentially variable level of construct expression among cells. To overcome this concern, we generated stable transformants of SH-SY5Y cells overexpressing WT myc-Prx2 and again found that SNOC pretreatment significantly inhibited the protective function of Prx2 against oxidative stress-induced cell death (Fig. 3E) . Importantly, Prx2 overexpression did not affect the known intracellular localization of the endogenous protein in the cytoplasm (Fig. 3F) . Moreover, these overexpression models have pathophysiological relevance because Prx2 levels also increase in human PD brains, compared with normal controls (Fig. 4D, lanes  1 and 2 vs. lanes 6 and 7; lanes 8 and 9 vs. lanes 10, 11, and 12 ).
SNO-Prx2 in PD Cell-Based Models and Human PD Brains. The fact that nitrosative stress is thought to contribute to a number of neurodegenerative disorders such as PD (17, 18, 21, 41) prompted us to ask whether SNO-Prx2 could be detected in cell-based models of PD and human PD brains. First, we incubated dopaminergic SH-SY5Y cells with the mitochondrial complex I inhibitor rotenone or 1-methyl-4-phenylpyridinium iodide (MPP ϩ ), each of which injures or kills neurons and induces a Parkinsonian phenotype at least, in part, in an NO-dependent fashion (21) . Exposure to rotenone or MPP ϩ led to the generation of SNO-Prx2 in these cells, but this effect was (D) Brain tissues from controls, AD patients, or PD patients were subjected to the biotin-switch assay to detect SNO-Prx2 in vivo. Equal amounts of total protein were loaded, and Prx2 in patient samples was detected by immunoblotting. (E) Ratio of increased SNO-Prx2 formation in PD models and in human brains. NMDA, NMDA-stimulated primary neurons; rotenone, 2 M rotenone-exposed SH-SY5Y cells; MPP ϩ , 5 mM MPP ϩ -exposed SH-SY5Y cells for 6 h; AD, brain tissues from AD patient; PD, brain tissues from PD patient. Blots from the biotin-switch assay and Western blot analyses were quantified by densitometry, and the relative ratio of SNO-Prx2 to total Prx2 was calculated. * , P Ͻ 0.05 (n ϭ 3-5).
completely prevented (for rotenone) or partially inhibited (after MMP ϩ ) by the NOS inhibitor, NNA (Fig. 4 A and B) . We found only low levels of overoxidized Prx (PrxSO 2/3 H) under the conditions assayed for SNO-Prx2, but much higher levels after exposure to H 2 O 2 (Fig. 4C) . To extend these findings to humans, we examined brains of patients manifesting PD with Lewy bodies obtained shortly after death (21) . We found evidence for significantly increased SNO-Prx2 levels in all five PD brains examined, but not in Alzheimer's disease (AD) or control brains obtained from patients who had died of disorders not of CNS origin (Fig. 4 D and E ). To determine whether the level of SNO-Prx2 in PD human brain is of pathophysiological significance, we calculated the ratio of SNO-Prx2 (by biotin-switch assay) to total Prx2 (from Western blotting) and found that this ratio was comparable to that encountered in our neuronal cell models manifesting cell death (Fig. 4E ). This finding indicates that pathophysiologically relevant amounts of SNO-Prx2 are present in human brains with PD.
Discussion
Prx family proteins are important antioxidant enzymes that limit accumulation of intracellular peroxides by redox reactions at certain key cysteine residues. Prx2 is extremely abundant in the brain (42) . Our data demonstrate a previously unrecognized relationship between NO and oxidative stress in neurodegenerative disorders, showing that Prx2 is S-nitrosylated in vitro, in cell-based models of PD, and in human PD brain tissue. Snitrosylation targets the redox-active Cys-51 and Cys-172 residues, which are both critical for Prx2 activity (40) , thus inhibiting its neuroprotective function against oxidative stress. SNO-Prx2 formation, resulting in Prx2 dysfunction, therefore provides a mechanistic link between nitrosative/oxidative stress and neurodegeneration. Because the cysteine motifs are conserved in all Prx containing dual-thiol-active sites (Prx1-4), we hypothesize that each of them may be a target of S-nitrosylation, and that NO therefore regulates metabolism of intracellular peroxides through S-nitrosylation of these active sites.
Active Prx2 reduces H 2 O 2 and other peroxides to form a sulfenic acid (ϪSOH; Fig. 5, I ). In turn, this adduct can either be reduced by another active Prx2 to form an intermolecular disulfide bond (S-S; Fig. 5, II) or overoxidized to produce sulfinic (ϪSO 2 H) or sulfonic acid (ϪSO 3 H; Fig. 5, III) . Both the disulfide and overoxidized forms can be regenerated to their active states by coordinated action of the thioredoxin pathway (thioredoxin reductase, thioredoxin, and NADPH) and the sulfiredoxin pathway (1, 2, 43). By using this normal redox cycle, Prx2 detoxifies intracellular peroxides. In the present study, however, we found that SNO-Prx2, produced after nitrosative stress, cannot reduce peroxides (Fig. 5,  IV) . Thus, S-nitrosylation of Prx2, generating nonfunctional Prx2, interrupts the normal redox cycle and results in accumulation of cellular peroxides, inducing oxidative stress. Higher concentrations of peroxides, however, can probably further oxidize SNO-Prx2 to Prx2-SO 2/3 H (dashed line in Fig. 5) (23) . PD results primarily from the loss of dopaminergic neurons in the substantia nigra; these neurons are particularly vulnerable to oxidative stress, in part, because of the oxidizing nature of dopamine. Interfering with the normal antioxidant system by the generation of SNO-Prx2 may contribute to neuronal cell death. Evidence for increased SNO-Prx2 formation in cell-based models of PD and human PD brain tissue strongly supports this mechanism. Our elucidation of an NOmediated pathway leading to neuronal cell death involving Prx2 dysfunction may lead to the development of new therapeutic approaches for sporadic PD and other neurodegenerative disorders associated with nitrosative/oxidative stress.
Materials and Methods
Chemicals and Antibodies. Hepes, ascorbate, S-nitrosoglutathione, hydrogen peroxide, methyl methane thiosulfonate, NNA, propidium iodide (PI), rotenone, MPP ϩ , mercury chloride, and DAN were purchased from Sigma-Aldrich (St. Louis, MO). Biotin-HPDP and immobilized avidin were from Pierce Chemical (Rockford, IL). Anti-Prx2 and anti-PrxSO 2/3 H were obtained from Lab Frontier (Seoul, Korea). Anti-myc-agarose beads were from Santa Cruz Biotechnology (Santa Cruz, CA). Fluorescein diacetate and Hoechst 33342 were from Invitrogen (Carlsbad, CA). Primers for site-directed mutagenesis were from Sigma-Genosys (The Woodlands, TX). All reagents were of analytical grade. with 0.4 mM L-arginine, and then replaced in the original conditioned medium for an additional 4.5 h. Cell lysates and brain tissue extracts were prepared in HENTS buffer [250 mM Hepes (pH 7.7), 1 mM EDTA, 0.1 mM neocuproine, 0.1% SDS, and 1% Triton X-100). By protein assay, cell lysates typically contained 500-g and 1.7-mg tissue samples. Blocking buffer (2.5% SDS and 20 mM methyl methane thiosulfonate) in HEN buffer [250 mM Hepes (pH 7.7), 1 mM EDTA, and 0.1 mM neocuproine] was mixed with samples and incubated for 30 min at 50°C to block free thiol groups. After removing excess methyl methane thiosulfonate by acetone precipitation, nitrosothiols were reduced to thiols with 1 mM ascorbate. Newly formed thiols were then linked with the sulfhydryl-specific biotinylating reagent N- [6-biotinamido] -hexyl]-LЈ-(2Јpyridyldithio) propionamide. Biotinylated proteins were pulled down with Streptavidin-agarose beads, and immunoblot analysis detected the amount of total Prx2. SNO-Prx2 was detected by the biotin-switch assay (15, 17, 21) . Site-Directed Mutagenesis of Prx2. Mutant Prx2 plasmids were constructed by using the myc-Prx2 plasmid as a template. The following sets of forward and reverse primers were used to introduce mutations at Cys-51, Cys-70, and Cys-172: C51A, CTGGACTTCACTTTTGTGGCCCCCACCGAGATC (forward) and GATCTCGGTGGGGGCCACAAAAGTGAA-GTCCAG (reverse); C70A, TTCCGGAAGCGCTGAAGTG-CTGGGCGTC (forward) and GACGCCCAGCACTTCAG-CGCCCAGCTTGCGGAA (reverse); and C172A, GAGCAT-GGGGAAGTTGCTCCCGCTGGCTGGAAG (forward) and CTTCCAGCCAGCGGGAGCAACTTCCCCATGCTC (reverse). The double-mutant C51A/C172A plasmid was constructed by using the C172A myc-Prx2 plasmid as a template. All mutant plasmids were constructed by using the QuikChange II kit (Stratagene, La Jolla, CA). Mutagenesis was confirmed by automated nucleotide sequencing.
Expression and Purification of Recombinant Prx2. WT Prx2 cDNA was cloned into a pGEX-4T-2 vector and expressed in BL21 cells according to the manufacturer's instructions (Amersham Biosciences, Piscataway, NJ). GST-fused Prx2 was purified on a column of glutathione Sepharose beads (MicroSpin GST Purification Module), and fusion proteins were treated with thrombin to remove GST.
Reduction of H2O2 by Prx2. Recombinant Prx2 was exposed to 200 M SNOC for 30 min at room temperature. After desalting by using a Bio-Spin 6 column, Prx2 or SNO-Prx2 was incubated with 50 M H 2 O 2 for 20 min at room temperature. The H 2 O 2 concentration in the reaction mixture was then measured with a hydrogen peroxide assay kit (A22188; Invitrogen) according to the manufacturer's instructions. For cell-based models, SH-SY5Y cells or SH-SY5Y cells stably expressing WT-Prx2 or double-mutant Prx2(C51A/C172A) were pretreated with 200 M SNOC for 30 min. After removing the medium and washing the cells once with PBS, the cells were further treated with 50 M H 2 O 2 for 10 min. The H 2 O 2 level remaining in the media was then determined with a hydrogen peroxide assay kit.
Cell Death and Viability Assays. SH-SY5Y cells were transiently transfected by using Lipofectamine 2000 (with Ϸ40% transfection efficiency as judged by GFP labeling). Twenty-four hours later, cells were exposed to 200 M SNOC. Thirty minutes later, medium with or without 600 M H 2 O 2 replaced the old medium. Cells were cultured for an additional 24 h and then stained with PI to assess death and with Hoechst 33342 for total cell count (44) . SH-SY5Y cells stably overexpressing Myc-Prx2 also were compared in viability assays with WT SH-SY5Y cells. Cells were exposed to 200 M SNOC; 30 min later, fresh medium with or without 600 M H 2 O 2 replaced the old medium. Cells were cultured for another 24 h and incubated with fluorescein diacetate, which is taken up and cleaved to fluorescein in viable cells. Fluorescence intensity was measured at an emission wavelength of 510 nm and an excitation wavelength of 493 nm (45) (46) (47) .
Cell-Based Models of PD and Human PD Brains. SH-SY5Y cells were grown in DMEM containing 10% FCS in a 5% CO 2 atmosphere. After cells were incubated with rotenone (4.5 h) or MPP ϩ (2 or 6 h), SNO-Prx2 was detected by using the biotin-switch method. To inhibit NOS activity, 1 mM NNA was added to the medium 1 h before rotenone or MPP ϩ exposure. Human brain samples were analyzed with institutional permission under California and National Institutes of Health guidelines (21) . Informed consent was obtained following the procedures of the Institutional Review Boards of the University of California at San Diego and the Burnham Institute for Medical Research.
Statistics. Data are expressed as mean Ϯ SEM. Statistical significance was determined by ANOVA, followed by a post hoc Scheffé test. Each experiment was performed in triplicate.
